Herbert D. Aronow, MD, reviewed the many ways the reimbursement landscape is changing thanks to new Medicare policies. “This is a really exciting time in the renal denervation space," he said. 

In 2024, a Denver cardiologist was sentenced to 158 years to life in prison for drugging and sexually assaulting multiple women he met through online dating apps. Six of his victims have now filed a civil lawsuit that claims the apps are “hospitable to serial predators.”

When the devices needed for a specific procedure were not available, a group of surgeons got creative. Their one-of-a-kind approach was a success, and the patient has experienced no complications.

ASE President David Wiener detailed some of the many ways imaging societies need to adapt now that so many imagers are specializing in multiple modalities. It may be time to change how annual conferences are scheduled, for example, so that the costs of travel are easier to manage.

Hospitals located in more competitive markets may be more likely to perform TAVR instead of SAVR, according to a new analysis of more than 130,000 patients. Is this a reason for concern?

A fifth-generation TAVR valve from Edwards Lifesciences was associated with improved outcomes compared to the device's predecessors in a new real-world analysis out of Cedars Sinai.

On Dec. 11, the Alaskan cardiologist was captured as part of a months-long investigation and charged with 10 counts of possessing child sexual abuse materials. The fire at his home occurred two days later.

After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14. 

The new guidance, published in JACC, focuses on three classes of commonly used anticancer therapies.

There is a risk of certain pericardial patches not being as strong or durable as needed. Customers are urged to identify, quarantine and replace these devices.

It is still unclear which imaging exams President Donald Trump underwent to evaluate his cardiovascular health. The White House shared a memo Monday as an attempt to put this topic to bed—but questions remain. 

Hemostemix believes its new cell therapy platform can help treat peripheral artery disease, congestive heart failure, cardiomyopathy and other serious medical conditions. The company plans on scooping up multiple practices to conduct additional research and increase the use of its platform. 

Physicians love AI scribes. Has anyone thought to ask patients what they think?

The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy."